Dr. Falk Pharma GMBH vs. Ellodi Pharmaceuticals LP

Explore the PTAB proceeding IPR2025-00054 filed by Dr. Falk Pharma GMBH on 2024-10-24. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2025-00054

Filing Date

2024-10-24

Accorded Filing Date

2024-10-24

Institution Decision Date

2025-06-03

Last Modified Date

2026-03-30

Proceeding Type

IPR

Termination Date

2026-01-23

Trial Status

Terminated-Adverse Judgment

Parties & Counsel

Petitioner

Dr. Falk Pharma GMBH

Represented By

Luman, Nathanaelet al

Patent Owner / Respondent

Ellodi Pharmaceuticals LP

Represented By

Sukduang, Sanyaet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 16821464

Respondent Patent Number 11246828

External Links

Espacenet

Google Patents

Respondent Inventor Stephen PERRETT et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

121 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name COOLEY LLP - ATTN: IP Docketing Department

Customer Number 58249

Address 1299 Pennsylvania Avenue, NW, Suite 700, Washington, DC, 20004, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
33885	William Galliani	650-843-5622
34262	C Talbot	703-456-8072
36343	Matthew Langer	212-497-6000
40673	Heidi Keefe	650-843-5000
41087	Christopher Hutter	703-456-8506
42669	Brian Hopkins	617-937-2300
42764	Cynthia Kozakiewicz	617-937-2300
43210	Michael Tuscan	202-842-7802
43255	Bonnie Mcleod	202-842-7800
44047	Matthew Brigham	650-843-5000
44546	Kimberly Bolin	650-543-5000
44614	William Christiansen Ii	206-452-8700
45409	Heidi Erlacher	617-937-2325
45899	Christina Stock	617-937-2300
47777	Mika Mayer	650-843-5000
47938	William Shear	858-550-6000
48199	Lisa Amii	650-843-5000
48907	Dean Fanelli	202-776-2050
50572	Matthew Pavao	617-937-2300
51909	Carol Laherty	206-452-8700
52292	Connie Tong	650-843-5000
55854	Scott Weston	617-937-2327
56393	Daniel Knauss	317-582-0173
57835	Phillip Morton	703-456-8000
59129	Jeffery Wyzykowski	202-842-7800
59307	David Hopkins	720-566-4063
60024	Robert Wu	650-943-5000
61254	Alla Brukman	202-842-7800
61689	Margaret Fischofer	703-456-8000
62305	Jennifer Volk	703-456-8575
63322	Eamonn Gardner	858-550-6086
64349	Andrew Keith	202-842-7800
64497	Madhuri Roy	650-843-5000
64911	Mark Rogel	206-452-8700
65144	Samuel Whitt	202-776-2316
65421	Orion Armon	720-566-4119
66418	Jonathan Cousin	202-842-7800
67971	David Holly	202-842-7800
68766	Kenichi Hartman	650-843-5227
68774	Kassity Mai	202-452-8800
69078	Bethany Roahrig	720-466-4178
70120	Jeremy Binstock	703-456-8000
70211	Jason Valentine	202-728-7157
70786	Marcelo Pomeranz	858-550-6146
70897	Amy Motomura	310-883-6559
71499	Joanna Hubberts	650-843-5098
71583	Lesly Steinbeck	212-479-6561
72201	Michael Mcevoy	202-842-7800
72629	Anders Fernstrom	703-456-8117
73102	Michael Winternitz	202-728-7034
73162	Thomas Paxton	617-937-2473
73384	Chen Chen	617-937-2384
73445	Xiaomin Su	202-776-2295
73668	Aeraj Haque	312-881-6714
73724	Lawrence Teague	206-452-8700
73852	Jordan Phelan	202-728-7066
74178	Fraser Brown	202-842-7850
74347	Newman Han	202-728-7047
75031	Xiaozhen Yu	202-728-7127
75736	Xixi Sun	617-477-2458
76165	Fumin Shi	202-776-2064
76239	Dustin Knight	571-643-5164
76259	John Masters	312-881-6407
76373	Eric Owens	212-479-6656
76421	Meera Govindaraghavan	202-663-7410
76534	Mengke Mccullough	858-550-6118
76605	Matthew Scheideman	202-842-7858
76692	Asako Nagashima	202-728-7054
76824	Claudia Frehe	202-842-7800
76859	Nadeen Nsouli	312-881-6698
76906	Jessica Cande	617-937-2348
77360	Audrey Gallagher	312-881-6717
77479	Yin Nelson	202-776-2088
77606	Andrew Henderson	425-503-7202
77755	Scott Shaw	650-843-5000
77802	Robert Powers	617-937-2490
77848	Jordan Degayner	312-881-6392
77930	Mark Westwood	650-843-5005
78052	Alexia Dilg	202-842-7815
78279	Christine Dunne	617-937-2337
78292	Elizabeth Baez	703-727-4270
78433	David Schachter	212-479-6815
78664	Jill Kozumbo	202-962-8384
78703	Brendan Roach	202-776-2180
79013	Candace Britton	650-543-5000
79226	David Duron	650-843-5604
79280	Rachel Preston	202-776-2315
79296	Celeste Alvarez	858-550-6000
79442	Peter Chung	703-456-8587
79458	Sam Matthews	617-937-2388
79575	Felipe Guzman	617-937-2381
79769	Stephanie Johnson	631-943-0991
79828	Dou Yeon Youn	212-479-6381
80140	Philip Wdowiak	312-881-6697
80181	Natalie Hendrick	617-937-1387
80447	Claire Tourkin	650-843-5138
80682	Mengran Liu	650-843-5114
80739	Zhipeng Zheng	202-776-2043
80762	Taylor Canady	212-479-6000
80787	Jennifer Costigliola	919-491-1109
80800	Luke Sande	617-937-2367
81166	Nitasha Bennett	858-550-6480
81181	Georgia Calhoun	858-550-6181
81333	John Habibi	202-776-2137
81446	Ashley Sherrid	206-452-8824
81515	Nina Gu	617-937-1459
81534	Elif Ertem Bekdemir	617-937-2354
81599	Daniel Manson	212-479-6835
81740	Tian Yong Zheng	206-452-8774
81797	Rei Li	212-479-6084
81816	Michael Minsch Iv	212-479-6610
81920	Ying Yiu	206-452-8825
81992	Daniel Hinton	617-937-2403
82124	John Kozlowski	858-550-6056
82294	Kathleen Dinapoli	202-842-7800
82583	Maxwell Gonzalez	650-843-5434
82694	Austin Thind	703-456-8593
82984	Sarah Robbins	202-776-2034
83259	Ethan Decicco	617-937-2312
L1396	Shanxi Feng	202-776-2259
L1408	Gesa Junge	212-479-6658

Proceeding Documents

136

3101

Ex. 3101 Email correspondence Exhibit

2026-01-29 FILING PARTY: BOARD

Download

Adverse judgment: post-institution ADVRSJUDG

2026-01-23 FILING PARTY: BOARD

Download

Patent Owner's Motion to Terminate and Request for Adverse Judgment MOTION

2026-01-20 FILING PARTY: PATENT OWNER

Download

Patent Owner's Updated Exhibit List NOTICE

2026-01-20 FILING PARTY: PATENT OWNER

Download

2031

Disclaimer of U.S. Patent No. 11,246,828 Exhibit

2026-01-20 FILING PARTY: PATENT OWNER

Download

Dr. Falk Pharma GMBH vs. Ellodi Pharmaceuticals LP

Proceeding Overview

Parties & Counsel

Petitioner

Dr. Falk Pharma GMBH

Represented By

Patent Owner / Respondent

Ellodi Pharmaceuticals LP

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Ex. 3101 Email correspondence Exhibit

Adverse judgment: post-institution ADVRSJUDG

Patent Owner's Motion to Terminate and Request for Adverse Judgment MOTION

Patent Owner's Updated Exhibit List NOTICE

Disclaimer of U.S. Patent No. 11,246,828 Exhibit

Petitioner's Request for Oral Argument OTHER

Order: Authorizing Patent Owner’s Motion to Terminate ORDER

Ex. 3002 Attorney Correspondence Exhibit

The American Heritage Dictionary of the English Language, 4th ed., 2000 - Definitions of “disintegrate” and “dissolve” Exhibit

ZOFRAN® (ondansetron) FDA-approved package insert Exhibit

Petitioner's Updated Exhibit List NOTICE

CLARITIN® (loratadine) FDA-approved package insert Exhibit

U.S. Patent No. 8,771,729 to Perrett et al. Exhibit

Narmada et al., “Formulation, evaluation and optimization of fast dissolving tablets containing amlodipine besylate by sublimation method,” ARS Pharmaceutica, 50:129-144 (2009) Exhibit

U.S. Patent Publication No. 20090022799 to Barman Exhibit

Declaration of Alan F. Parr, Pharm.D., Ph.D. supporting Petitioner Reply for U.S. Patent Nos. 10,632,069, 11,246,828, and 9,486,407 Exhibit

Khan et al., “Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets,” AAPS PharmSciTech 8:E1-E7 (2007) Exhibit

Schoepfer et al., “Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis,” Clinical Gastroenterology and Hepatology, 17:1477- 1488 (2019). Exhibit

U.S. Federal Trade Commission (FTC), To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy, Chapter 4: Competition Perspectives on Substantive Standards of Patentability (2003) Exhibit

PEPCID® (famotidine) FDA-approved package insert Exhibit

U.S. Patent Publication No. 20080132535 to Singh et al. Exhibit

Judgment Against Ellodi in Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma GmbH, Case No. 4b O 43/24, Regional Court of Dusseldorf, Germany (Feb. 27, 2025) – Original German Language Exhibit

U.S. Publication No. US20110189299 to Okubo and Davies et al. Exhibit

Judgment Against Ellodi in Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma GmbH, Case No. 4b O 43/24, Regional Court of Dusseldorf, Germany (Feb. 27, 2025) – Certified English Language Translation Exhibit

2024-10-23 Transcript of Oral Hearing Dismissing Complaint, Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma, Case No. 24-cv- 01392-PTG (E.D. Va) Exhibit

2025-07-02 Deposition transcript of Dr. Martyn Davies in IPR2024- 01197 Exhibit

Comment of the U.S. Federal Trade Commission (FTC), Terminal Disclaimer Practice to Obvoiusate Nonstatutory Double Patenting, PTO-P-2024-0003 (2024) Exhibit

Petitioner’s Reply Brief, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024-01197, Paper 20 (PTAB 2025) Exhibit

2025-11-19 Deposition transcript of Dr. Martyn Davies in IPR2025- 00052, IPR2025-00054, and IPR2025-00055 Exhibit

2021-04-19 Assignment of U.S. Patent Application No. 16/821,464 (which issued as U.S. 11,246,828) from Adare Pharmaceuticals US, L.P. to Ellodi Pharmaceuticals, L.P. recorded at Reel 055965, Frame 0893. Exhibit

Judgment Granting Request for Adverse Judgment after Institution of Trial, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024-01197, Paper 41 (PTAB 2025) Exhibit

Petitioner's Reply Brief REPLYTOOPP

International Publication No. WO2003074029 to McEntee et al. Exhibit

CLARINEX® (desloratadine) FDA-approved package insert Exhibit

U.S. Patent No. 7,384,921 to Tang et al. Exhibit

Teitelbaum et al., Eosinophilic esophagitis in children: Immunopathological analysis and response to fluticasone propionate,” Gastroenterology Exhibit

U.S. Patent Publication No. 20050019393 to Augsburger et al. Exhibit

International Publication No. WO2009078872 to Martin et al. Exhibit

Than, “Individualized Drugs for Individual Needs,” Review of Optometry, 146:38-43 (2009) Exhibit

Decision Granting Instituting of IPR, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024-01197, Paper 10 (PTAB 2025) Exhibit

U.S. Patent Publication No. 20030124184 to Mezaache et al. Exhibit

Ex. 3001 Exhibit

November 3, 2025 Oral Hearing Transcript Regarding IPR2025-00052, IPR2025-00054, IPR2025-00055, and IPR2025-00056 Exhibit

Petitioner's Updated Exhibit List NOTICE

Joint Stipulation to Modify Due Dates 2-3 NOTICE

Petitioner's Revised Notice of Deposition of Dr. Martyn Christopher Davies NOTICE

Order: Conduct of the Proceeding; Extending Word Limit for Reply and Sur-Reply 37 C.F.R. sec. 42.5a ORDER

Patent Owner's Opposition to Petitioner's Motion for Additional Discovery OPPOSITION

Petitioner's Motion For Additional Discovery MOTION

Petitioner's Notice of Deposition of Dr. Martyn Christopher Davies NOTICE

Petitioner's Updated Mandatory Notice NOTICE

Petitioner's Supplemental Mandatory Notice: Related Matters Section NOTICE

General Order: Related Matters Updates ORDER

Petitioner's Objections to Admissibility of Patent Owner's Evidence OTHER

Transcript of the August 29, 2025 Deposition of Alan F. Parr, Pharm.D., Ph.D. from Nos. IPR2025-00052, IPR2025-00054, and IPR2025-00055 Exhibit

Patent Owner's Response RESPONSE

Transcript of the August 25, 2025 deposition of Alan Parr, Pharm.D. from No. IPR2024-01197 Exhibit

U.S. Patent 9,867,780 Exhibit

Transcript from the July 2, 2025 Deposition of Martyn Christopher Davies, Ph.D. from No. IPR2024-01197 Exhibit

Jorveza® label Exhibit

Clinical Trials Study, “Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)(FLUTE),” Exhibit

U.S. Patent No. 8,324,192 Exhibit

Geoffrey Lee, Report on Measurement of Disintegration Time of Jorveza® 1 mg Schmelztabletten Exhibit

“Lozenge” Definition, Dennis B. Worthen (ed.), Dictionary of Pharmacy (2004) Exhibit

Transcript of the April 9, 2025 Deposition of Alan F. Parr, Pharm.D., Ph.D. from No. IPR2024-01197 Exhibit

Cordova-Fraga T, Sosa M, Wiechers C, et al., Effects of anatomical position on esophageal transit time: a biomagnetic diagnostic technique. World J Gastroenterol 14:5707–11 (2008) Exhibit